<SEC-DOCUMENT>0001628280-23-027303.txt : 20230803
<SEC-HEADER>0001628280-23-027303.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803164128
ACCESSION NUMBER:		0001628280-23-027303
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		231140829

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20230802.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:bce04f5a-399f-4491-bf0e-818c10639fd6,g:89e65a70-4447-4479-ab09-883a159f6a60,d:28563cd4de374486bcdcda5686460932--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20230802</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20230802.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i28563cd4de374486bcdcda5686460932_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:48.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 2, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"></td><td style="width:22.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.600%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_______________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">240.12b-2 of this chapter).          Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i28563cd4de374486bcdcda5686460932_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Item 1.01             Entry into a Material Definitive Agreement.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Amendment to Second Amended and Restated Loan and Security Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On August 2, 2023 (the &#8220;Closing Date&#8221;), X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) and its subsidiary X4 Therapeutics, Inc. (together with the Company, the &#8220;Borrowers&#8221;) entered into an amendment (the &#8220;Amendment&#8221;) to the Existing Loan Agreement (as defined below) with Hercules Capital, Inc., as agent and lender, and Hercules Capital Funding IV LLC and Hercules Capital Funding Trust 2022-1, as lenders (collectively, &#8220;Hercules&#8221;), which provides for aggregate maximum borrowings of up to $115.0 million, of which $32.5 million (the &#8220;Conversion Balance&#8221;) was previously outstanding under the Second Amended and Restated Loan and Security Agreement, dated as of January 6, 2023 (the &#8220;Original Closing Date&#8221;), by and among the Borrowers and Hercules (the &#8220;Existing Loan Agreement&#8221; and as amended by the Amendment, the &#8220;Amended Loan Agreement&#8221;).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Amendment upsizes the Company&#8217;s existing facilities and provides for a term loan facility of up to $115.0 million, including: (i) the $32.5 million Conversion Balance, which was deemed borrowed upon entering into the Amendment, (ii) a $22.5 million tranche, which the Company drew on the Closing Date of the Amendment, (iii) an additional tranche of up to $20.0 million, which will be available in either one or two drawings following U.S. approval of mavorixafor in individuals with WHIM syndrome (&#8220;Approval&#8221;) until the earlier of (A) 45 days following Approval and (B) September 30, 2024 in the case of the first drawing, and until December 15, 2024 in the case of a second drawing, (iv) an additional tranche of $7.5 million, which will be available following achievement of a certain clinical development-related milestone through the earlier of (A) 45 days following achievement of such milestone and (B) December 15, 2024 and (v) an additional tranche of up to $32.5 million, which will be available subject to approval by Hercules in its sole discretion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrowings under the Amended Loan Agreement continue to bear interest at a variable rate equal to the greater of (i) 10.15% or (ii) 3.15% plus the Wall Street Journal prime rate. In an event of default (as defined in the Amended Loan Agreement) and until such event is no longer continuing, the interest rate applicable to borrowings under the Amended Loan Agreement would be increased by 4.0%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrowings under the Amended Loan Agreement are repayable in monthly interest-only payments through March 1, 2025, and in equal monthly payments of principal and accrued interest from April 1, 2025 (the &#8220;Amortization Date&#8221;) until the maturity date of the loans. The Amortization Date may be extended (i) to October 1, 2026, if Approval occurs on or prior to September 30, 2026, and (ii) to the maturity date if an extension pursuant to the foregoing clause (i) has occurred and no event of default occurs. The loans mature on October 1, 2026; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided, however</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, such maturity date will be extended to July 1, 2027 if the Amortization Date is extended pursuant to clause (i) of the foregoing sentence. At the Company&#8217;s option, the Company may prepay all, but not less than all, of the outstanding borrowings, subject to a prepayment premium that remains unchanged from the Existing Loan Agreement &#8211; 3.0% during the first 12 months following the Original Closing Date, 2.0% during the following 12 months and 1.0% thereafter. In addition, the Amendment provides for payment by the Borrowers to Hercules of an additional fee equal to 3.5% of the aggregate principal amount of loans drawn under the Amended Loan Agreement (excluding the Conversion Balance), payable upon the earlier of maturity or the repayment in full of all obligations under the Amended Loan Agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Borrowings under the Amended Loan Agreement continue to be collateralized by substantially all of the Borrowers&#8217; personal property and other assets except for their intellectual property (but including rights to payment and proceeds from the sale, licensing or disposition of the intellectual property). The affirmative and negative covenants to which the Borrowers will remain subject remain largely unchanged from the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Existing Loan Agreement. However, the Borrowers have agreed to certain updated financial and performance covenants. Prior to January 31, 2025, the Borrower must maintain Qualified Cash (as defined in the Amended Loan Agreement) in an aggregate amount equal to at least $20.0 million. On and after January 31, 2025, such amount must equal at least 20% of the aggregate principal amount of loans outstanding under the Amended Loan Agreement. The performance covenant remains unchanged from the Existing Loan Agreement &#8211; from and after January 31, 2025, the Borrower must maintain trailing six month net product revenue of at least 55% of its forecast as approved by the Company&#8217;s Board of Directors (the &#8220;Performance Covenant&#8221;). However, the Performance Covenant will be waived during any period in which (i) the Borrowers maintain Qualified Cash in an aggregate amount equal to at least 75% of loans outstanding under the Amended Loan Agreement or (ii) both (x) the Company maintains a market capitalization of at least $450.0 million and (y) the Borrowers maintain Qualified Cash in an aggregate amount equal to at least 45% of loans outstanding. The Borrowers&#8217; obligations under the Amended Loan Agreement continue to be subject to acceleration upon occurrence of specified events of default, including payment default, insolvency and a material adverse change in the Borrowers&#8217; business, operations or financial or other condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The foregoing description of the Amendment and the Amended Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:81pt;text-indent:-81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.03             Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment and the Amended Loan Agreement is incorporated by reference into this Item 2.03.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Item 7.01             Regulation FD Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%">On August 3, 2023, the Company issued a press release announcing the entry of the Amendment. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%">The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%">This Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company&#8217;s expectations with respect to the loan facility with Hercules and the achievement of milestones thereunder. The words &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks described under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which is on file with the SEC, and risks described in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="a991xforpressreleaseaug320.htm">Press Release, dated August 3, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i28563cd4de374486bcdcda5686460932_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991xforpressreleaseaug320.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i17080cee8d934758ad13e4499db7f60e_58"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;Exhibit 99.1</font></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:111px"></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON, August 3, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">X4 Pharmaceuticals</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Nasdaq&#58; XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE&#58; HTGC) (&#8220;Hercules&#8221;). The company also announced that it drew down $22.5 million upon the transaction&#8217;s closing.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;This expanded loan facility creates significant financial flexibility for X4 as we continue preparations for the potential commercial launch of mavorixafor in individuals with WHIM syndrome and continue to advance mavorixafor for certain chronic neutropenic disorders,&#8221; said </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Adam Mostafa, Chief Financial Officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals. &#8220;The initial draw down not only </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">strengthens our balance sheet on a non-dilutive basis and extends our projected cash runway into 2025, but the overall transaction also creates expanded, future optionality beyond the equity capital markets as we potentially commence product sales and monetize a priority review voucher next year.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;Hercules is very pleased to continue to support X4 and expand our partnership ahead of the potential approval and commercial launch of mavorixafor in WHIM syndrome and expected upcoming development progress in potentially treating certain chronic neutropenic disorders,&#34; said Bryan Jadot, Senior Managing Director and Head of Life Sciences at Hercules Capital. &#34;This substantial capital commitment from Hercules aims to assist X4 in further advancing its important mission of developing and commercializing novel therapies for the treatment of rare diseases of the immune system.&#34;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The term loan facility provides for up to $115 million of term loans in the aggregate, available to be funded in multiple tranches. In addition to its initial drawdown, X4 may, for a period of time following U.S. approval of mavorixafor in individuals with WHIM syndrome, draw an additional tranche of up to $20 million. An additional tranche will be available to X4 in the amount of up to $7.5 million for a period of time following achievement of a certain clinical development-related milestone. The availability of a final tranche of up to $32.5 million in support of X4&#8217;s growth initiatives is subject to the approval of the lenders. In addition, the availability of each tranche is subject to certain customary conditions to drawing. The facility refinances $32.5 million in outstanding principal indebtedness and extends the initial interest-only period and maturity of existing and future borrowings. X4 is under no obligation to draw funds in the future.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About X4 Pharmaceuticals </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on the discovery and development of novel therapies for people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. Following announcement of positive data from our global, pivotal, 4WHIM Phase 3 clinical trial, we are currently preparing a U.S. regulatory submission seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with WHIM syndrome. We are also currently evaluating mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following positive results from a Phase 1b clinical trial of mavorixafor in people with congenital, idiopathic, or cyclic neutropenia. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.x4pharma.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the anticipated benefit of the term loan facility funding and achievement of related milestones&#59; the availability of unfunded tranches in the future&#59; X4&#8217;s plans and expected timing for its clinical and regulatory developments of </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mavorixafor in individuals with WHIM syndrome and certain chronic neutropenic disorders&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and the plans and objectives of management for future operations and capital expenditures</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, risks and uncertainties related to X4&#8217;s ability to raise additional funding when needed and on acceptable terms to X4 in order to achieve its business goals, including to repay the term loan facility&#59; the availability of future tranches under the term loan facility is dependent, in part, on the approval of the lender, achievement of certain milestones and other factors&#59; uncertainties inherent in the initiation and completion of clinical trials and clinical development&#59; regulatory uncertainties&#59; X4&#8217;s ability to obtain marketing approval from the applicable regulatory authorities in any jurisdiction for </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">mavorixafor, if approved</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; X4&#8217;s ability to protect its intellectual property rights&#59; the impacts of general macroeconomic and geopolitical conditions, rising inflation, and uncertain credit and financial markets on X4&#8217;s business, clinical trials, and financial position&#59; and other risks and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 4, 2023, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel Ferry (investors)</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director, LifeSci Advisors</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">daniel&#64;lifesciadvisors.com</font><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(617) 430-7576</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brett Whelan (media)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bwhelan&#64;lifescicomms.com </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20230802.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bce04f5a-399f-4491-bf0e-818c10639fd6,g:89e65a70-4447-4479-ab09-883a159f6a60-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20230802" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20230802">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20230802_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bce04f5a-399f-4491-bf0e-818c10639fd6,g:89e65a70-4447-4479-ab09-883a159f6a60-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_25db4c67-7e1d-4164-9150-59590c5e15f1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e858fa83-9312-4e78-845a-3b4518b7c7ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_936a4306-4e99-4588-85ca-9d2832b7a320_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_254f123d-7f26-4030-949d-dcc78efabead_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_764e90ac-dfe6-4345-9b67-cdcd1665aae4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6041aae6-dcb8-4f31-b023-8cd49d8fc232_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_62db3934-686f-484f-ab08-3c7b79e3ce31_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b0c31743-a0c8-42cd-aa22-e30dfab8c765_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_62abf9b6-233c-40e4-bf70-0ca4c5a30242_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_534a43d7-c344-4f5d-814e-b8b197fe5262_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a2dc7390-4172-4c67-8819-e49c07a73bec_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7b663eeb-62ce-4645-b7d0-a575015ef845_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1e79420e-1893-4b05-8fb0-93502945995b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_96b38b12-9d4b-4778-bc12-889ce2da1147_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2918a2b8-81b7-4246-8183-72236db474f4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b91db3a3-8a90-45de-9d59-d57cc332a98f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_30d97586-87de-419c-bc79-7c3a6b9ee46a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1c525628-0b32-4dea-8ec3-d13d7b96e2be_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7d2344ab-405e-4592-9586-52ecde3b1ecf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_901d84ed-3476-45ae-85c7-84051b0f9309_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e9601c66-e699-4dc6-9ba0-a8dbf15b8754_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_406ec8b3-f33a-451d-bf3b-2180ded7377a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_22a5d9f3-4e1e-4faa-a5a4-50265610e931_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a8023239-b2b4-4ba6-a9d1-4af860ac688d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20230802_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bce04f5a-399f-4491-bf0e-818c10639fd6,g:89e65a70-4447-4479-ab09-883a159f6a60-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20230802.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1213694e-9dcd-4b2a-afc6-7bce54b447fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_DocumentType_1213694e-9dcd-4b2a-afc6-7bce54b447fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_615c4b01-3048-4db6-8486-4e387a149835" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_DocumentPeriodEndDate_615c4b01-3048-4db6-8486-4e387a149835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_77418b0e-edda-4985-bad2-76788b17b98a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityRegistrantName_77418b0e-edda-4985-bad2-76788b17b98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cfe16af9-e610-4460-a9e6-7ce97683b362" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cfe16af9-e610-4460-a9e6-7ce97683b362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a722f29a-a7e0-412f-aadd-bfe7e1713e63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityFileNumber_a722f29a-a7e0-412f-aadd-bfe7e1713e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_34ebf2be-7ec5-410f-bb4d-9363e6e8063e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityTaxIdentificationNumber_34ebf2be-7ec5-410f-bb4d-9363e6e8063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6c7b7d33-7a6f-4570-ae32-6f1c4168fe3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityAddressAddressLine1_6c7b7d33-7a6f-4570-ae32-6f1c4168fe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e9a41137-f6c9-445c-a455-a8cf895013b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityAddressAddressLine2_e9a41137-f6c9-445c-a455-a8cf895013b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4742c28e-1e34-4244-aeb4-7d08267a0f13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityAddressCityOrTown_4742c28e-1e34-4244-aeb4-7d08267a0f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2c9c86e1-fda2-46e9-ac21-b2fde53984a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityAddressStateOrProvince_2c9c86e1-fda2-46e9-ac21-b2fde53984a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0198bc90-8b92-4f0a-90fd-a3956e218522" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityAddressPostalZipCode_0198bc90-8b92-4f0a-90fd-a3956e218522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_998c0657-8ab2-4076-b7cd-627d50226213" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_CityAreaCode_998c0657-8ab2-4076-b7cd-627d50226213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ccad033a-30c9-4175-8ff5-78a48d50c042" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_LocalPhoneNumber_ccad033a-30c9-4175-8ff5-78a48d50c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_57c3d36d-6dde-4f4f-83b6-004c09dc8778" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_WrittenCommunications_57c3d36d-6dde-4f4f-83b6-004c09dc8778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6dfcbf32-6173-41bb-89ce-21c1e08a779a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_SolicitingMaterial_6dfcbf32-6173-41bb-89ce-21c1e08a779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d1d87530-5cd8-44ad-92ff-f3165aa1ed53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_PreCommencementTenderOffer_d1d87530-5cd8-44ad-92ff-f3165aa1ed53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_51f5b965-ec2f-44c4-b4e0-68783d3c398c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_51f5b965-ec2f-44c4-b4e0-68783d3c398c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_120e607f-96c3-42ef-b6ca-0d0d67f9d307" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_Security12bTitle_120e607f-96c3-42ef-b6ca-0d0d67f9d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_92d9483d-0e44-44ad-a09b-a003a73e52b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_TradingSymbol_92d9483d-0e44-44ad-a09b-a003a73e52b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e6af0442-6d0f-40be-bd92-abd3e9c8fe48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_SecurityExchangeName_e6af0442-6d0f-40be-bd92-abd3e9c8fe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_99c7093c-dd77-4116-bf43-4f40e8909f51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityEmergingGrowthCompany_99c7093c-dd77-4116-bf43-4f40e8909f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_3ae6cf80-6f9d-495d-b138-e6b6d1aa994b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityExTransitionPeriod_3ae6cf80-6f9d-495d-b138-e6b6d1aa994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_518edf11-5103-4ae4-ac07-82258da906b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_EntityCentralIndexKey_518edf11-5103-4ae4-ac07-82258da906b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_da6de07e-ad32-4639-913f-57a3c5e9378e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9ac884-617a-44fa-8137-55ddb46c229d" xlink:to="loc_dei_AmendmentFlag_da6de07e-ad32-4639-913f-57a3c5e9378e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #% /\# 2(  A$! Q$!_\0
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MC(]:* "BBB@ HHW#UHS0 4444 %%%&: "BC(SC-!('4T %%%% !11D8S1F@
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M8N1$>C" $R-GMM4YQQ7D8CB2:J6HPT[O_(^KRS@"KB;1J-N3^S!7?_!/%?V
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M2;AG%#,!U- #"5(Q7S;_ ,%!_P!I71/A?X!F^%ECI%KJ6K>(K-XY(KI0\=I
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MGMK7XB>/--T:2\5GM5OKH1F55(!(SUQD?G6"/VN?V9">?CAX=_\ !@M?,?\
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MX+N>U?\ !-W]E>"SL8_V@/'6FV\DMTO_ !3=M-$2T"9(-QSQEA]T@'"\Y^;
M^Q\8X4U%:64-E;QVEK;K%%$@6.*-0%11T ':INV-M?G>,Q=3&5W5G]W9'[;E
M>74<KPD:-)>K[OJQK8VD-7PC_P %%?V3D\'ZG+\>?A[I5M!HUTR#7K.'Y3!<
MO(0)P"<;7+*I"@8;YL'<Q'W<5;-4]?\ #VD^)=&N= U_3(;RQO(&BNK6XC#)
M*C#!4@]0158'&5,#B%4C\UW1&;971S;".C/?=/LS\;2P]*#Z5[#^V-^R_K7[
M.WQ!FETO2YO^$5U*?=H=XTAD$?&3 YQPZ\XSDLN#EB&QX\/3I7Z)AZU/$454
MAK<_%,7A:V#Q$J-56DG;_@@"R-O5L%3E6':OO/\ X)\_M<6OCK0;?X*_$/6Y
MI/$%FI_LN[NF!%W .D>[KO4>N21WXQ7P7D]*N^&_$FO>#M?M?%'AG4YK._L9
MQ-:W4#8:-QW'^>>]<^8X&GCJ')UZ/S.[)LVK95BU5C\+TDNZ_K8^S/\ @HE^
MR.VJ0R?'3X8^'))+S<S^);>W;)D0#BX"8Y8?Q8[<X/-?$_>OU _90_:.\-_M
M*_"^-=2O;>37K6V$/B+3?)"?,1C>$).8V]>F<C Z5\??MU?LHCX$^,%\8>";
M"Z;POJ\C,KLNY+&X)),!;.<$<KN XXR<&O)R?'2HU'@L1HUM_E_D?0\2972Q
M%)9GA-8R^*W3S_S\SP*ALXR!2;ATHW#&17TVY\/8]W^"W[?'C;X#^ K7X?>"
M/AOX=^S6Y9YKB<3M+<2$_-(Y\SEC[< 8    KK!_P5>^-0/_ "3_ ,,_]\W'
M_P =KY;[T<],UYLLJR^<G)PNWYL]FGQ!G%&*A"K9+1*RT2/J;_AZ]\:_^B>>
M&?\ OFX_^.T'_@J]\:>C?#SPS_WS<?\ QROEG;00!4_V1EO\GXLU_P!9,\_Y
M_/\  ]*_:1_:?\8_M,ZAI.I>+]"TVQ;289HH%TY9,.'922V]F_N]L5YJ.M&6
M]:4=:[J%&GAZ:ITU9(\?%8BMBJSJUI-R>_Y"U;\/ZU<>&_$.G^([2%))M/O8
MKF-),[69'# '';(JI2,">U:27-%IF<92C)2CNCZC7_@JY\:4_P":?>&?^^;C
M_P".4I_X*O?&HC'_  KSPU_WS<?_ !ROEK@'&*"/:O,_L?+=_9GM+B3.[6]L
M_N/TZ_8J_:)\5?M)_#W4_&'BO1+"QN+'6FLHX]/5PK((8WR=[,<Y<]\8 KV9
M#VKY9_X)0'_BQ_B#G_F;)/\ TFMZ^I4/S8KXG,:,:&-J4X:),_6,EKU<3E5*
MK4E=M:CZ&SBB@\C%<1ZAROQ8^)GAWX/^ -3^(7BB7%KIMN9/+615>=_X8DW$
M LQP ,\DU^6GQR^,GB7X\_$B^^(WB:-(9+I@EM9QN62VA'W(U)Y..23W)) &
M<#])/VAOV6/!/[2:Z;!XY\1Z]:P:6SM#:Z7?)'$[-@;W5XVRP P#U 8^M>9_
M\.JOV>,?\C-XL_\ !A;_ /QBO>RG&8# ISJ7<_39'QO$>5YQFM14J-E36NKM
M=_\  /SZW+Z494\8K]!?^'57[/&<?\)-XL_\&%O_ /&*7_AU3^SR.GB;Q9_X
M,;?_ .1Z]S_6++_/[CY7_4O-_P"[]Y\0_!7X1^(/CA\2--^'/ASY);Z3]]=-
M"SI:PCEI&"@\ >N 20,C.:_5#X0_"WP]\'? &F?#SPS%_HVG6XC\YHT5YW_B
ME?8 "S'DG%<W^SW^RU\-?V;+34+?P*;ZXEU*97N+O5)(I)L*,! R1K\O?![F
MO2@<'I7SN;9E]>J<L=(+9'VO#F0K*:+G5M[27X+L244TR -MQ2LV.U>.?3BT
M,,KBDW>U ;/:@#C/C?\ !/P5\>/ %UX#\<:;YL<@WV=PK;9+6< [94;!VL,^
MA!!((()!_+/XJ?"OQE\&?&]WX"\<Z4UM>VK_ "MUCN(B?EEC./F1L<'MR#@@
M@?KXZ@BO,OVA/V4/AE^THNFOX\DU*WN-+WBVNM-NEC?8^-R$,K*02 >F<C@X
MR#[.4YJ\#4<9ZQ?X>:/E^(N'UFU/GI651;/NNS/RNW+_ ':-R]A7Z#'_ ()4
M_L\CKXF\6?\ @QM__C%)_P .JOV>,<>)O%G_ (,+?_XQ7T/^L67[:_<?&?ZE
MYOVC]Y\7? CX[>-OV?/'$/C7P9=Y'$>H6$K_ +F]ASRC#^3=5/([@_I7;W'P
MO_:O^",D$5ZM]HGB"Q"7'V.X*O"_!*YP"'1P."!R.1@D5Y-_PZJ_9Z&"/%'B
MS_P86_\ \8KT[]GS]F'P9^S;::AI?@;7]8N;7495EFM]4FAD5) ,;U*1(V2,
M#!)''0=:\3-,=@<9RU:-U-=;;_\ #'U/#^5YME_-0Q%G2ETO>W?[^I^<?[0_
MP,\0?L^_$R]\ ZUYDUNK>9IM^T)1;NW8_*X[9[$ G!!&:X<8(X%?K!\?/V<_
M '[1GA>W\,>/!=1I:77GV]Y8-&L\1P055G1L*W&0!SM7TKR,?\$JOV>?^AH\
M6?\ @PM__C%>GA>(:/L4J]^9=MGYGA9AP7C/K4GAFG#I=VMY'Y][E_NT;E_N
MU^@O_#JK]GC_ *&;Q9_X,+?_ .,4H_X)5?L\'IXE\6?^#&W_ /C%='^L67^?
MW''_ *EYQ_=^\_/G<O\ =H++CBOT&'_!*K]G@]/$WBS_ ,&-O_\ &*#_ ,$J
M?V>1P/$WBS_P86__ ,8H_P!8L!Y_<+_4O..T?O/SY/TI<8/2O=_VY_V8/ 7[
M-&N>'=,\":CJEQ'JUK<27!U.XCD*E&0#;L1,?>/7->$<@UZN&Q$,7156#=F?
M.X[!ULOQ4J%3=;_/46D?ITI:T_!6BVOB7QIH_AV^:18+_5+>VF:,@,%>15)&
M<\X/H:VG+EBY/H<\(NI)175V,HE0<$4?+Z5^@@_X)5?L]#[WB7Q9_P"#&W_^
M,4O_  ZI_9Z[>)O%G_@PM_\ XQ7B?ZQ9?UO]Q]5_J7G&]H_>5/\ @D\P_P"%
M'>(!CKXJD_\ 2:WKZE7KP*X+]GS]G3P9^S?X7O/"7@?4-1N+:^U!KR9M2F21
MQ(41, HB<80=B<]Z[Y00>E?'XZM#$8R=2.S=S]*R?"U,#EM*A4WBK,=0V<44
MC?=/TKE/2,:S\?>!M2U=M T_QEI<^H*[(UC#J$;3!E^\-@.[(P<\<8JU?^)?
M#FEW]MI.J:[9V]U>-BSMIKI$DG/HBDY;\ :_!'P;K'_!//38OVA9/BK\*/BG
M<?&U?CQXP/A/Q5\+]/U*&]$1O,06B7L'[F+?)YBN&&=LG) (-=)^UIXO^+O[
M,/QH_P"">7C;]M^?6KKQ5X1T^[NO&.R!K_4-J7T#1H4B!:6983$I49;<ISDY
M->K'*^:2C%OKTWLKZ:ZKI\]CQO[4Y8N4HJUUL]M;:Z:/J?N;?:UI6FSV]G?Z
MG;V\EU+Y=K'/,JM,_7:H)^8X[#FC4]:TC1K=;K6=5M[2-Y5C62ZF6-6=C@*"
MQ')/0=37Y:?M,_\ !1K]GK]M;]M7]DOPG\&M,\96]UHWQI6[O&\3>#;S3(S&
MUG*@V/.BAVR?NCG'-<M_P7B\=^.?VI_VD[7]E#X*_%>#1_\ A4'@FY\=ZN[W
M44$7]M1,KV4$DDL@C<^6KLJ;6974<?-BL*>7U)5(PE>-U=Z;):&]3,81IRG'
M6S27G<_7/6/$&A^'K,ZCX@UBUL;<,%-Q>7"QH">VYB!4>A>*O#7BB%[KPWXB
ML=0CC?:\EC=I,JMC."5)P:_*'_@K#^U/X4_;-_X-^-#^/_A;4WN?[6U31X]4
M$LB-+!?1!TN(Y-GRAQ(#D#IFO'_@YXC^"OB/]LG]GSPY_P $:/!/C;P]KFD:
MA%=_&SPS?6VI6.BOIYBB22^N(;APCR,CSA')P2L. <"M(9;*5'F;::<EMHK=
MW?2_H9U,SY:RC%)IJ+6NKOV5NA^WT/BCPW<ZW)X;MO$%C)J,2;YK&.[0S(O'
MS% =P'(YQW%+<>)?#UKK,/ARZUVSCU"X0O;V,ETBS2J,_,J$[B/E;D#L?2OQ
M2\9_%?Q]^S+_ ,'%7C;]I/2M,%QX.A\1^'_!?CJ960-;0:U;A+>4EB D:7%H
MCO(3A53;U<5T&F?$#Q1^T;_P<<?#?]I?^WI)O"%KX[\7?#WP;9S!6VQZ)X=9
MKFXAD0;)+>:YOII$(9F!W@XP "66N.O-IR\U_/L-9EKR\NO-:WEW/V2U#6]&
MTCR3JVJV]K]JN%@MOM$RIYLS?=C7)^9C@X4<FK"NO4-7Y&?\%TO%NO\ [9G[
M5-C^PO\ "+XTQ^'9_@K\,]6^*6L1VNH1PW%]XCC@5=&TZ$DHT=V#,CJ0X(BU
M N,LBX](_;N_X+">(;7_ ((R^!_VQ_@&DVC^)OC!=V?AW3[Z&$.N@:@WVA=0
M91+@N(C97D44F#EO*<J5R*S^H5)0IM;R_#M]Z-?[0I*I-/[/X]_Q/T8A\;>#
M;C7#X9MO%NFR:D"0VGI?1F<8&3\F=W YZ=*J7'Q6^%]I/)9WGQ'T&&:&0I)%
M+K$*LC X((+<$>E?,OP!_P"",'[%WP(N?"?Q"M-#UO5OB5X;O+:_NOBC>Z]=
M?VOJUU%('D:=C(5:*49B>+!!A.PD_>/YR_LN+_P2'U#XB_&#0/VW?V7O$'C#
MQY>?M#>*(;35]/\ ".JWD"V;7^V&-IK5A&N',A(/(#9/&**>%HU%-Q<GRVV2
M_P ]A5,76I\BDHKFONW_ );G[D#Q%H+W5M81ZY:-->0F:SA^TKOGC R709RR
MX(Y&11=:_H5E>+IE]K-K#</"TJ02W"J[1K]YPI.=H[GH*^'_ (R>%] \#_\
M!:#]EKP7X4TY++2](^$/BNRTVSC)*P6\4$"1Q@DDD*J@<G/%/_:<T'1O$_\
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M'<6LZR1M@D'#*2#@@CZBF:#XD\.^)[5K_P -Z]9ZA LGEO-8W23(K8!VDJ2
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140429999761248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>xfor-20230802_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20230802.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ +H4#5ZK$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  NA0-799!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ +H4#5YE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  NA0-7T8:8CV0$   E$0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ +H4#5Y^@&_"Q @
MX@P   T              ( !J P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  NA0-7EXJ[',     3 @  "P              @ &$#P  7W)E;',O+G)E
M;'-02P$"% ,4    "  NA0-7JL0B%C,!   B @  #P              @ %M
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ +H4#5R0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ +H4#5V60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20230802.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="xfor-20230802.htm">xfor-20230802.htm</File>
    <File>a991xforpressreleaseaug320.htm</File>
    <File>xfor-20230802.xsd</File>
    <File>xfor-20230802_lab.xml</File>
    <File>xfor-20230802_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xfor-20230802.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "xfor-20230802.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xfor-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.x4pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xfor-20230802.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-027303-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-027303-xbrl.zip
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M*D0_'ZY13+C1M53+\84D^1AT&/,AF@<=%H0JMH\E4ZT "TDJ'B_'XBK>UQ<
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M'&/-D];J*J"8<^0RM@[36H@45E#CP]A7?CB:^/SHS>/6Y ]G'<N^%%&;<\!
MH,[^JWT"S"Z!^$0<4#73^!J662615=Q1E:%VDD+X.](AO[[]ATK)(M0/+M@1
MQ7CPF&O/325;XF*_(Y3H_(2CNN1 <61*P22<=1GS9"Z1DOH@,J"(T>+@F2J!
M7G":PT_7O73*8VU-Z!"D=*(V![3U05[&'VX(1H@&>A5Y^)F+BU*;6EMDFB7Y
MZ5,Q8H"[)3KDL7T+E<A_P7V+%]B#>!F16:',#?*3-M/5.7*/*7((-E,&,@T]
MXZG.EQ7J!9!3F5"U'7C6,V,D@UREOE6:5W,R9[,X&9E@GA(Y24WQ;V!;?6=H
MG\KQ-M$&5_%*KJ$3O9SI<8H6%(^BEI(?!KG4V4%%]B5K53Y$,I9:JAXP&\TV
MM[(.R_.7*[2Q$MIEZ/T6PZT:KH-X#74@LM?G.25_T/89=(@RN5ZL- (L+];I
MD10_36T],7!'O\C%9YC75/YXGMB<=XS>AU1XV/$#ATY1*,K)TZL"4OH)4K)\
M9YFKES7-W,![RG$1B0N"WE=2.,/30NXT(9@+QRI>W9@!VQHEVS-$%LJ#)H25
M/1S/^8UZ78!<540$A''UID#JQQ;I\D.C61 #'>S,GAS4Q@I0-6LOV-AM?)5Y
MVUYT>%V7^4S?O:>=IR3H0A[ _%9V,;$*OF0A^BI>/9":X\(K,#?0PTW2_?GY
M3>JA]\:2D^^IJEJ ;Q"#Y5:GY-$N)X#B&?I,H687"F)ND;^:_-9M*>P![]L5
M?%IT2W+_'#&WAJI>R*0*=R#&4E\42#TW_"Q@I/T6",5^SQ@RR0KB57J"@7<%
M"B7[#"!93+WC91+36;XIE6J"(??U3I"*ZL=\P+-0?EXW@3#@-=;@\R0?/<#;
M#?&$O&76_IUZ?[A"; 4+TV=FYC,,SDZ$?:32("D]J>%-4+U.5BG/ [QJL%?K
MZ(*49RX\T'606'@ \9Y3*CQ0WXY-55.BZ\G'3!HN"]<&X T!Q0?IK0'D<CBL
M)3$3N1EC.O-4"!3#/'>>WSGR:J2)!]E73@D$%\A6D5*\>05'6DS<5ZHMFN=&
MO*]![;8(A@HO6A"&QT11W?*07F.J374N6<FV%K3)*'M@N%U3 -.>+X !!HE]
MC>R/'X /I>N',A;LP$!:7A23EV0X6K.4\TD<CW-[.@LD\: PFF94I $8;3=-
M0#!5 C2OK0URFNE+?%$> H@_C$7 Y5BKSK-$;W:[AD4P6Z/J*KPU7(2-.#CA
MKP'-\U*9@YZZ*JDP('L5'8DB7JIX: U,#IHX,#O)WG'BUBHCE%8 J/P5&D&I
M<U19Q75GPU,7U4(!0145:,%%4KEU3@?I#KH:$=PVJ2?1_EE)!RU9]2/:0=WH
MHIR9Y!:8K#[GYJP/OI/'YKS_*A:\@]_O)W>NX0 C%F"^IGRA,L'/"<=4>UHJ
M0M,S')BX+M= H)SO <C:IS#\JCP#K%-1^RR'M?I54@!<GMD7],%5R#%,@/(3
MH&0&E*)ZXA!/& U4ZFJH^.M*\#L,'PI\_ G^EQCX:X;<ES-TMUF4*1P5 @I@
MX@F$.)I%\SDU'^7)U?D2$K2'B?N]S$26ZT;*U5NIT9S;,\^VRZ5.5"N=H,7H
M/L13%(F(H[]9344\>8;Y1TP71&S^S8#Y.,G\XS3T67P>^][\0U@6GRP96V-A
M_JF^UVG^Z83.YA]-0087GH7X*77PW!9>"(:7HR\^#G];LH8(4XH+3^5X&73W
MI8=(' D<X5.!5$9KI8B,NZ3%&ZN2KW3/UO M:$\?66PT5EH/M=\:)D\$ 6F/
MAC$97C$J4M] -L;@&%8$H:0*^I+84]&,>!PO6LD"2H@MLH0.(AKO55.?J=?0
M )0E'O:TPY(ER21;MU:T"LE"D'.QH"",P=>;H/N(V1'@?,RX%,5-;3%P^54F
MP=V@8/:P*$8'>PE-KJ$A^:@'22F3:(!OCJ5@7KUUG22LG+2>A*M-7;2@)3NC
M]W'GEPZK*5HFJ8U?.9ORE<FRQ4I &,:X&PL4#=:Q3\H1*4V*6A-T#?U*U+X\
ME:DQ5]N3J#G"8353,NEJ$EZ&#HK4E$^D-J]Y/(0'PE1^5KU8Q]?I$=H!<]76
M)2P #X05K'TU 3++CR19B7LNMW6)OZ?\G_W 6,=PNNV=#HPY.W^S:=T[VVAN
M^"GW;1;;L8R6\R2?%7[Y&[4W\!RS'$H7@HMGNW?EL.#/$T,W!6L&JC()L*11
M0LSK(_ORC^REX>-%:/SA";\< Q_RA/+>K],Y+,@Q97  EZRL1LJZ0'0XW%N2
M5"_.8VZ2$>@I9Q1;P9KHTH-W25;_S8LOD(P%7IY NUWK 5PNY=DE*34:CQS;
M-,;1I')RI7)MU_I%>E2EG.@#?4#GW8X_DN:SS,:?5./A3K4@5YCB.L<:6ZH.
M;&'9'-5?TCK"S20/PZ%"?N5<N8[DU_?7GXB7?,#Z>(E1W.7ZGX.Z3GFGA/&W
M;*P=2/BR^4EK_![*JSMJ_5BWIV,S>[/[5<]_O#B]_7)]=G/@J5FUVJNY$G3!
M?H^Y8%D)_P9;!LMNG?&P/%IE"CR=Q]!W^:=E%T D>!'J7?@!&U-_F*;UE<E+
M&NB<*/11P]$X&H<"BS!W3">4-KKMIIWM:Z^DR/,&X2 MAJDE9MLHO-$TNG;C
MR>/EEN&83_\QOOV,ZK0-L[W9L!NZ.KM^NVSK3Q@]WV?D-@R:5W^A?C&0FK-V
M5G/-)35/B=E#^-;<"Q)N1= +#G^/S'G\+^H.OR@ZWL]Z6P#_&B"JRSHY]>B$
M?,9OK0WI+LFK%Y.^)TLCO"@)7BWZ7Q.2^V/.AL6J/O79//&M8>F!A6;U0>C-
MX'_C:.*?_#]02P,$%     @ +H4#5Y0]*1!K @  < <  !$   !X9F]R+3(P
M,C,P.# R+GAS9,U56V^;,!1^SZ_P>)X#A#0%U*326E6:E%W4M5K?)@.'8!5L
M9IN&_OO:#E9*VVR-M(?Q$,PYWW?NQSD[[YL:/8"0E+.E%TX##P'+>4'99NG=
MWESAV#M?329G'S"^^W2]1I<\[QI@"ET(( H*M*6J0JH"]).+>_I T/>:J)*+
M!N.5I5WP]E'03:70+)A%#N:T(LUR".;E"<%1DI1X/D]"G)4!X#B,\S!81$E9
M+#YNTCB!Q0DY#31B?JI_3A-,LB#!<1R1\"0I%V016*.]3&5>04.03HW)M)=+
MKU*J37U_N]U.M]&4BXT_"X+0O_NR_F&AWH"M*;L?H?M,U X?^4:=$0D.WNL\
MQ_!Y6Q'1D&G.&]^D&\3!S$-$*4&S3L&5KLLEE*2KU=+KV.^.U+2D4.BBUV#*
M.@(\4RLB-J"^D@9D2W)XA]/5!"%3"]JT7"C$WJ0.Q0B3)/%[DYV'=K5;\YPH
M.Q('BV'QV!QQ.,-1..UEX?GO<CLV1)E4A.5PC&_]A1WO7\2P[^QQ,3C>\3%8
M8Q+RZ88_^ 50T[G9V^[E(;@Y8',8^R2,<67Y1C+(VI:RDN\$6F0"3UWTUU"Z
MB7ZU 6^,B'VE1.2"UW^9)[\5O 6A*,CGVV,-5 +*I6=V"+NI_563;*HC<9!7
M#L8M,&I?4Z!>[S-Q7/78:J[4#:AA5YO_.?%6P+&):XK45X9M])'Y&_Z-UB-:
M++T+KN]_#QG9[?7GPU>+=;H#.VO.7@$E9=1.7&"?$.']7P5&EG7FO\2^L-))
M*+ZQE3V_3&X@#Y _$'-2YUU]/&\?UD':('3%&Y;+'V_7[OO9!EK!;JU7DR=0
M2P,$%     @ +H4#5W_0N>[X"@  ^F0  !4   !X9F]R+3(P,C,P.# R7VQA
M8BYX;6S575UOVS@6?>^OT&9?=H%A+7Y((HMI!]U,9U%LIRW:#&:PBX7!+R7"
MV%(@*TWR[Y>2[<2**5ND8E7[TCCVU>6YQSKW7I(*^^-/=\M%\$V7JZS(7Y_!
ME^%9H'-9J"R_?'WVV\4O@)[]].;%BQ__ L ?__CR(?BYD#=+G5?!>:EYI55P
MFU57076E@]^+\L_L&P\^+WB5%N42@#?-9>?%]7V975Y5 0H1WIIM/RU?":E#
MDD8<8,920 B#0*2A!A12"<,8LU3%/UR^HDS'$4]"8T$2\T_" !<A Y1B#B.6
MQCP.&Z>++/_S5?V/X"L=F/#R5?/KZ[.KJKI^-9O=WMZ^O!/EXF517LY0&.+9
MUOIL8WZW9W^+&VO(&)LUGSZ8KC*;H7$+9W_\^N&KO-)+#K)\5?%<U@.LLE>K
MYLT/A>15P_I17$&G1?T;V)J!^BT $<#PY=U*G;UY$01K.LIBH;_H-*A__O;E
M?>>0;%9;S')]67^WGW69%>IKQ<OJ Q=Z8= WWJK[:_WZ;)4MKQ=Z^]Y5J5.[
MVT59MKS6*%F-$L8URK]V#38; /^9\%;[6)\!7!/NQ^?">(C3C\\&]\)D"'UZ
MP#O##(:\OJ'>Y6JL>_=AJ,'03X_XN6Z+HN*+$6Z+QV%V("_J-SZ85YMA:D<'
MDFDSSB9U[T#5=Y7.E5YGRY;K(%.OS\RKN=+9_%U>9=7]N:E\)5^\-Q?<_4O?
MSU&D!)%Q A(-%2 P)H#!* 01BU@H(PVC%,ZKAYMZKG/PV]?M^,T@1T8X<XBM
MZM!HJ5?%32D?J]MR82M9IEK5]8W.<K[4JVN^N<# K%N!-?(W:Y#!!F70P P,
MSA]GCR'Y$+DX/3V+B3%3R!:61=T.%.73Z MY//I'?:T,\";TE98O+XMO,W.M
MH0"A^@6H7S2RZO8XV_ORWI9;G+R41WC>6,QD87J=ZPJT*$_+8MDSH*KH^;VO
MJ3/#G@5%J71I.EA+");[[ZU2YLM?;7Z8)*+17-.(IIQBP+#)0$0G%%!2]Z6"
M1)"*1":"NXG9,LI$!;V!^,/V15"##2YN"U=AVXCM*^Z!=(TC<'>F/(1^@(D!
M8K=Y'5GP!P+;%_TA8U_A7_"[]\HDDRS-UM.OCS=+H<LYPS$G.(R-[AD#)*)&
M_)'D@"E$,1()QRAT$W_'2!--  9MT(8;K/&Z)H N@OLF@6>@;9Q$X,Z81R(X
MPL: 9-#E>>2$<"3 _:1P[(+GZPB@:>])"A%6($F1R0PA#@$C3 $E94)U:CQQ
M-;0C@!--"/8Z]RG7PSL".* C<*+K>W8$AYAZEHX GJ0CL*EEY(X NG0$<(#P
M+TI>KW-_O5^*8C%/8E/Z0RZ!2K41.R818,),[:62"L9QQ+DF?<7>\CPU@6_
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M*UP.K-C])CZ85V]>;-_)UO]5QIL7_P-02P,$%     @ +H4#5Y=,E"<#!P
M#S4  !4   !X9F]R+3(P,C,P.# R7W!R92YX;6S5FUMSV[82Q]_S*734U[,6
M;L3%$[OCXR9G/'4;3^)..^=%@\M"XI0B/10=R]_^@)2=QK'3LB8[9EXHBP*Y
MB__^""R6\.OO=YMB]A'K;5Z51W-Z0.8S+'T5\G)U-/_E\BWH^??'KUZ]_A?
M;_]Y?S[[H?+7&RR;V6F-ML$PN\F;]:Q9X^S7JOX]_VAG%X5M8E5O (Z[RTZK
MJ]LZ7ZV;&2.,WS>[_[4^=!Z)B)D%;DP$(0P%%PF"IMI3(KF)0?Y[=:@-RLPJ
MDEH(E0[*@'7$@-;<TLQ$:27I;EKDY>^'[<'9+<Y2]\IM]_5HOFZ:J\/%XN;F
MYF#GZN*@JE<+1@A?W+>>WS7?/6I_P[O6U!BSZ'[]U'2;/]4PW98N?OOI_(-?
MX\9"7FX;6_K6P#8_W'8GSRMOFT[UO_1K]M46[3>X;P;M*: ,.#W8;</\^-5L
MMI>CK@I\CW'6?O[R_NRA27&UMO7&'OAJLV@;+$ZK!$1RM;NTN;W"H_DVWUP5
M>']N76,\FN]2E*&-*=&$M0:_VU^X^,/N58W;!$O7S_-TXN[ZULK?]P%W#98!
M]_VZMU!4_D&CHE6U^G1E81T6W=EEP'S9W?7$;9O:^F:IK;%>:P&2*IN0BC9!
MQQ5D60A.2,^8"0^[W+J\33YW0=BB/UA5'Q?IQBD8C+5_M'KLM7AD;J_+\_R^
M?^HN4]LE991+(Q!,\ &$8Q9L]!)4>I(RX=*C$?T@MS^W]M#KS^-Y4OM950>L
MT[!Q;\[6_G%L'P![UV)Q9>MT(_#KO/BD<:RKS1BQ:JH1E-N');D[GZ5>1ZQK
M#.?[J'RU<UW/FC288M=RC(A?8)U7X4T9?DBC[5+2S M'*' B-(C@)&BA)0CD
M6EDJC.;9**%_8+87 VSZ##Q?RQ>&X4W9Y,WM>USEK1)E\[/=X%(I0;5+$R6&
MD-0P.@-G P,EE=:.*F>T'<3"4U9[H<"GB\)@)2=!PEG*T.JKJNZ$_Y#TQ]/J
MNFSJV],JX-)'I-)& RAIFRZEO,BFY F41Z.DYHY+-@(8?^I$+T[$U#D93^=)
M8/,V+_#GZXW#>FD58Y&9-/\I3+Y3%L':$%+FC0JIHAPE'X&1/RSV B*;.A#/
M5' 2T;^TN[.0M,ICOE]XW'6$"W21.02%/DL=(1&<$P$,EZD/J-,2#$= X2OF
M>W$AI\[%&-I. I*3$%((MG<?:<F&="F]<BIP#LK*M$#/TAK<(F<@(_6"2AV1
MNQ$ ><)T+SC4U.$8JNE$P6!+-%;05H<HO4FR9!ZLR#*PVD=M,D*YD_\(&*P7
M&/K; ^/O:3HE,$[3G^_JR^JF7 HEF&<:@2(7()@0B6TG0 6BF5261#I&;O'(
M<"\HS#<"Q3/UG!(27<+\KKZHJX]YZ7')O/%:(H48+ ,AT8#UC()C,6#&C196
MC<?%%];[U;'(-T+'$&FGA,A%M6UL\;_\JEM0$6JT\X: =B;U(A(+AL0 EIM,
M(J,Z8V,L7)^RW0^/"=<Y1Y+UA>%H1[V3&FWGMS':$YDIT-8EOXF2X)0/()D*
M60JK9 /GD<^M]0-@PD7.9TOWPB%O7X,5%^NJO%]8>V\#X=P")VT&1%4&.L8,
ME+9")^\]$<-&@2\M]@O]A(N:@R1\X?#_6N=-@^5IM=E<EW>+Y^TR4YX'+A.P
M(6 :LD0$G1)?($1X8H+72NE!##QIMA\($ZY:#A?SA6GX4!6YSYN\7/V4$IPZ
MM\52ANA=;)?&5/'$LG.@C4=@U%,DVBIEAKWF>&RS'P<3+E8.E/&%(;BHL248
M4V+;O;EM7_K7[V+R8QEHT"KC!#(?=!+$!C L1HB<RLQ:BB$;EA)\W78_*"9<
MJ1Q)UFG!<;;=7F/]>5\R&C-G9 ;H6;N=R MP @E(K70:!GU:# W;'?%7'O0#
M9<)5RU$E?ND)!?UUFA1O*7.7>5.T6T (2J(B&.G3.,@P@I/> @DD2!5-X&18
M$>)+B_UPF'"M<I"$+QS^R]JV.QD_W&Y<52P-"T8D0H&@$/MASA+CTH%PJSAF
MS-%!L7]@KE_@)UR/?+YX$WGHW^S\VI8K[#9YH+21")$2H$#2H$4<@@N&@76!
MH_$ZHABVI'C*:K^=4Q.N.@Z6<A+5QC<;K%<)Y?_6U4VS3I/;E2UOE\9X10SW
M$()2*26F$EP4O%TA$=2&F)@-&P[^Q'@_,"9?;QPN[#3XV*6QKMSFK?[[38)+
M;E'ZJ%-2DR8T$"8+X"C7@-+)0*TU1HSQTONQY7YD3+@0.8JDD\#B-.E5V^(L
M9;Z['_$VY;T:0Z04,DH2S18%6$\4:,8R':PA<I3WW5^8[0?$A,N3P\5\81I.
MTC(HM$NAMX5=+8.5 8E"L(&W[]JX 4-YA$Q9[C,T7.EA^Z4>F.L7_0G7))\O
MWFA1?[UX)-YY.G'\ZNZ']M#^_\SQJ_\#4$L! A0#%     @ +H4#5^N;O-L[
M#@  G#0  !X              ( !     &$Y.3%X9F]R<')E<W-R96QE87-E
M875G,S(P+FAT;5!+ 0(4 Q0    ( "Z% U<7%I$JA!H  #R?   1
M      "  7<.  !X9F]R+3(P,C,P.# R+FAT;5!+ 0(4 Q0    ( "Z% U>4
M/2D0:P(  ' '   1              "  2HI  !X9F]R+3(P,C,P.# R+GAS
M9%!+ 0(4 Q0    ( "Z% U=_T+GN^ H  /ID   5              "  <0K
M  !X9F]R+3(P,C,P.# R7VQA8BYX;6Q02P$"% ,4    "  NA0-7ETR4)P,'
M   /-0  %0              @ 'O-@  >&9O<BTR,#(S,#@P,E]P<F4N>&UL
64$L%!@     %  4 4 $  "4^      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
